试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-16
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
编号:NCT03992131登记状态:提前终止企业 / 申办者:pharmaand GmbH
药物 / 成分:Rucaparib、Lucitanib、Sacituzumab govitecan
登记的停止原因(原文):Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-16
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
编号:NCT04528199登记状态:提前终止企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:[18F]FLOR (FC303) Injection
登记的停止原因(原文):The Principal Investigator decided to terminate the study because the PI left Hopkins.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-16
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
编号:NCT04785547登记状态:提前终止企业 / 申办者:Prof. Christina Peters
药物 / 成分:Blinatumomab
登记的停止原因(原文):Terminated by Amgen Limited
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-16
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
编号:NCT05088967登记状态:提前终止企业 / 申办者:Innovent Biologics (Suzhou) Co. Ltd.
药物 / 成分:IBI110、sintilimab
登记的停止原因(原文):Development strategy adjustment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-12
Study Evaluating Betrixaban in Pediatric Participants
编号:NCT03346083登记状态:提前终止企业 / 申办者:Alexion Pharmaceuticals, Inc.
药物 / 成分:Betrixaban
登记的停止原因(原文):After completion of Part 1 and prior to initiating Part 2, the Sponsor decided to cease developing betrixaban, prompting early study closure.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-12
Pharmacokinetics and Safety of SAR441236
编号:NCT03705169登记状态:提前终止企业 / 申办者:National Institute of Allergy and Infectious Diseases (NIAID)
药物 / 成分:SAR441236、Placebo
登记的停止原因(原文):The study closed to enrollment and follow-up in May 2023. There had been no enrollment since October 2021, and by 2023, the available study product had reached its expiration date. Enrollment targets in Arm B had not been met.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-12
A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
编号:NCT03847272登记状态:提前终止企业 / 申办者:Centre Hospitalier Universitaire Dijon
药物 / 成分:prednisone and ustekinumab treatment、Ophthalmologic examination、Questionnaires、Blood samples
登记的停止原因(原文):The long inclusion period meant that the question could not be answered within an appropriate timeframe.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-12
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
编号:NCT04864782登记状态:提前终止企业 / 申办者:Qilu Pharmaceutical Co., Ltd.
药物 / 成分:QL1604、Paclitaxel injection、Cisplatin/Carboplatin
登记的停止原因(原文):Phase 2 completed, phase 3 sponsor decided to terminate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-11
Pentoxifylline Therapy in Biliary Atresia
编号:NCT01774487登记状态:提前终止企业 / 申办者:Baylor College of Medicine
药物 / 成分:Pentoxifylline
登记的停止原因(原文):Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-11
Diuretic/Cool Dialysate Trial
编号:NCT02593526登记状态:提前终止企业 / 申办者:University of New Mexico
药物 / 成分:Bumetanide、Cool Dialysate
查看官方原始记录 ↗